IN8bio (NASDAQ:INAB) Stock Rating Reaffirmed by HC Wainwright

IN8bio (NASDAQ:INAB)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $14.00 target price on the stock.

IN8bio Trading Down 5.7 %

NASDAQ INAB opened at $0.99 on Monday. The firm has a 50 day simple moving average of $1.00 and a 200-day simple moving average of $1.55. The firm has a market cap of $31.67 million, a price-to-earnings ratio of -0.88 and a beta of -0.22. IN8bio has a one year low of $0.89 and a one year high of $3.95. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.53 and a current ratio of 3.53.

Institutional Trading of IN8bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INAB. Voss Capital LLC grew its position in IN8bio by 35.5% in the 2nd quarter. Voss Capital LLC now owns 457,876 shares of the company’s stock valued at $705,000 after buying an additional 119,857 shares during the last quarter. Geode Capital Management LLC grew its position in IN8bio by 205.2% in the 2nd quarter. Geode Capital Management LLC now owns 176,561 shares of the company’s stock valued at $272,000 after buying an additional 118,715 shares during the last quarter. Sigma Planning Corp grew its position in IN8bio by 105.6% in the 1st quarter. Sigma Planning Corp now owns 203,900 shares of the company’s stock valued at $265,000 after buying an additional 104,750 shares during the last quarter. Rock Creek Group LP grew its position in IN8bio by 98.3% in the 3rd quarter. Rock Creek Group LP now owns 151,314 shares of the company’s stock valued at $157,000 after buying an additional 75,000 shares during the last quarter. Finally, State Street Corp purchased a new position in IN8bio in the 2nd quarter valued at $91,000. Institutional investors and hedge funds own 7.37% of the company’s stock.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.